Anavex Life Sciences’ (AVXL) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note released on Tuesday morning,Benzinga reports. They currently have a $42.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.66) EPS.

Separately, D. Boral Capital reiterated a “buy” rating and set a $46.00 target price on shares of Anavex Life Sciences in a research note on Wednesday, February 12th.

Anavex Life Sciences Stock Performance

AVXL opened at $8.68 on Tuesday. Anavex Life Sciences has a 1-year low of $3.25 and a 1-year high of $14.44. The company has a 50-day moving average of $9.97 and a 200-day moving average of $7.77. The company has a market capitalization of $738.32 million, a P/E ratio of -15.78 and a beta of 0.69.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. As a group, sell-side analysts expect that Anavex Life Sciences will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its stake in shares of Anavex Life Sciences by 102.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 1,708 shares during the period. Berkshire Money Management Inc. purchased a new stake in shares of Anavex Life Sciences during the fourth quarter worth $107,000. Prudential Financial Inc. acquired a new stake in shares of Anavex Life Sciences during the 4th quarter valued at about $109,000. Fiduciary Alliance LLC acquired a new position in Anavex Life Sciences in the fourth quarter worth approximately $119,000. Finally, D.A. Davidson & CO. bought a new position in Anavex Life Sciences during the fourth quarter valued at approximately $122,000. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.